News

November 30, 2015 4:30 pm
•FDA Approves Empliciti (Elotuzumab), a New Immune-Stimulating Therapy to Treat Multiple Myeloma – On November 30th,  the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat...
November 23, 2015 6:00 am
The Financial Toxicity of Cancer - One often overlooked side effect of cancer care is one that doesn’t affect your health, but rather your finances. Due to the diversity of health insurance plans, doctors may not always know the high costs...
November 20, 2015 9:15 am
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.
November 20, 2015 9:15 am
IMF Chairman Dr. Brian Durie will present “Myeloma 101: Updates on Treatment & Pain Management” during this informative teleconference, and will shed light on the most up-to-date therapies for myeloma patients.

Pages